Puma Biotechnology | PBYI - Current Liabilities


Puma Biotechnology reported $82.73M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amgen USD 25.5B 547M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Daiichi Sankyo JPY 765.7B 119.32B Jun/2026
Exelixis USD 361.93M 9.05M Jun/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
Incyte USD 1.31B 177.55M Jun/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Moderna USD 2.53B 139M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
Takeda JPY 2.76T 335.02B Jun/2026
TG Therapeutics USD 268.49M 81.38M Jun/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026